inarigivir

Small moleculeexperimental

Clinical trial activity

7 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2013 (NCT01803308)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@@H]1[C@H](OP(=O)(OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)SCOC(=O)OC(C)C)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O
Mol. weight
703.62 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • sb9200
  • sb9200
  • sb 9200
  • sb 9200

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04059198Phase 2Aug 31, 2019Pharmaceutical Research Associates, Inc. (PRA), Spring Bank Pharmaceuticals, Inc.
NCT04023721Phase 2Jun 18, 2019Pharmaceutical Research Associates, Inc. (PRA), Spring Bank Pharmaceuticals, Inc.
NCT03932513Phase 2Apr 11, 2019CSI Medical Research Pte Ltd, National University of Singapore, Spring Bank Pharmaceuticals, Inc.
NCT03493698Phase 1May 7, 2018Pharmaceutical Research Associates, Inc. (PRA), Spring Bank Pharmaceuticals, Inc.
NCT03434353Phase 2Feb 28, 2018Gilead Sciences, Spring Bank Pharmaceuticals, Inc.
NCT02751996Phase 2May 1, 2016Spring Bank Pharmaceuticals, Inc.
NCT01803308Phase 1Mar 1, 2013INC Research, Monash University, Spring Bank Pharmaceuticals, Inc.
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Spring Bank Pharmaceuticals, Inc.For profit7522013
Pharmaceutical Research Associates, Inc. (PRA)For profit3022018
CSI Medical Research Pte LtdFor profit1012019
Gilead SciencesFor profit1112018
INC ResearchFor profit1112013
Monash UniversityAcademic/Hospital1012013
National University of SingaporeAcademic/Hospital1012019
7 organizations
Page 1 / 1